Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy.
Lei JiXi ChenXiaoyan QianMin XiaoQing LiQiao LiJiayu WangYing FanYang LuoShanshan ChenFei MaBinghe XuPin ZhangPublished in: Breast (Edinburgh, Scotland) (2024)
MPR may be a novel pathologic end point in HR+/HER2-breast cancer after neoadjuvant chemotherapy, holding greater applicability in the prognosis evaluation than pCR.
Keyphrases
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- locally advanced
- lymph node
- sentinel lymph node
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- induced pluripotent stem cells
- pluripotent stem cells
- breast cancer risk
- real time pcr